GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
Source: SeekingAlpha
2026-03-18 08:00:22 ET
In the previous article, "GSK: Depemokimab and Jemperli Lead the Next Wave" , I talked primarily about Q3 earnings, the impact of the data from the Phase 2 study [ NCT04165772 ] on Jemperli's long-term prospects, and why, in my opinion, declining Zejula sales are no longer putting pressure on its stock....
Read the full article on Seeking Alpha
For further details see:
GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
Novartis AG
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
